FULC
Price
$7.83
Change
-$0.18 (-2.25%)
Updated
Jul 11 closing price
Capitalization
422.66M
25 days until earnings call
VRDN
Price
$17.04
Change
-$0.09 (-0.53%)
Updated
Jul 11 closing price
Capitalization
1.39B
25 days until earnings call
Interact to see
Advertisement

FULC vs VRDN

Header iconFULC vs VRDN Comparison
Open Charts FULC vs VRDNBanner chart's image
Fulcrum Therapeutics
Price$7.83
Change-$0.18 (-2.25%)
Volume$688.95K
Capitalization422.66M
Viridian Therapeutics
Price$17.04
Change-$0.09 (-0.53%)
Volume$477.6K
Capitalization1.39B
FULC vs VRDN Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. VRDN commentary
Jul 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Buy and VRDN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 12, 2025
Stock price -- (FULC: $8.01 vs. VRDN: $17.04)
Brand notoriety: FULC and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 102% vs. VRDN: 60%
Market capitalization -- FULC: $422.66M vs. VRDN: $1.39B
FULC [@Biotechnology] is valued at $422.66M. VRDN’s [@Biotechnology] market capitalization is $1.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • FULC’s TA Score: 4 bullish, 4 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FULC and VRDN are a good buy in the short-term.

Price Growth

FULC (@Biotechnology) experienced а +15.75% price change this week, while VRDN (@Biotechnology) price change was +8.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.52%. For the same industry, the average monthly price growth was +16.95%, and the average quarterly price growth was +21.18%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+9.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.39B) has a higher market cap than FULC($423M). FULC YTD gains are higher at: 66.596 vs. VRDN (-11.111). FULC has higher annual earnings (EBITDA): -8.94M vs. VRDN (-304.76M). VRDN has more cash in the bank: 637M vs. FULC (227M). FULC has less debt than VRDN: FULC (8.11M) vs VRDN (21.2M). FULC has higher revenues than VRDN: FULC (80M) vs VRDN (302K).
FULCVRDNFULC / VRDN
Capitalization423M1.39B30%
EBITDA-8.94M-304.76M3%
Gain YTD66.596-11.111-599%
P/E RatioN/AN/A-
Revenue80M302K26,490%
Total Cash227M637M36%
Total Debt8.11M21.2M38%
FUNDAMENTALS RATINGS
FULC vs VRDN: Fundamental Ratings
FULC
VRDN
OUTLOOK RATING
1..100
6216
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
8997
PRICE GROWTH RATING
1..100
3543
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (27) in the null industry is significantly better than the same rating for VRDN (95) in the Biotechnology industry. This means that FULC’s stock grew significantly faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as FULC (100) in the null industry. This means that VRDN’s stock grew similarly to FULC’s over the last 12 months.

FULC's SMR Rating (89) in the null industry is in the same range as VRDN (97) in the Biotechnology industry. This means that FULC’s stock grew similarly to VRDN’s over the last 12 months.

FULC's Price Growth Rating (35) in the null industry is in the same range as VRDN (43) in the Biotechnology industry. This means that FULC’s stock grew similarly to VRDN’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCVRDN
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GMVMF0.160.01
+8.29%
GMV Minerals, Inc.
BNZIF0.49N/A
N/A
BANCO INVEX S A INSTITUCION DE BANCA MULTIPLE INVEX GRUPO FINANCIERO
SRGHY15.28-0.31
-2.01%
Shoprite Holdings Ltd.
LVMHF570.00-21.55
-3.64%
LVMH-Moet Hennessy Louis Vuitton
ANSNF0.03N/A
-11.11%
Anson Resources

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-2.25%
SLS - FULC
48%
Loosely correlated
-2.90%
ANNX - FULC
40%
Loosely correlated
-6.86%
VRDN - FULC
39%
Loosely correlated
-0.53%
MRNA - FULC
36%
Loosely correlated
-1.87%
MLTX - FULC
34%
Loosely correlated
+0.25%
More